利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.04 秒)

    Compositions and methods for the identification, assessment, prevention and therapy of human cancers
    5.
    发明授权
    Compositions and methods for the identification, assessment, prevention and therapy of human cancers 失效
    用于鉴定，评估，预防和治疗人类癌症的组合物和方法

    公开(公告)号：US08080368B2

    公开(公告)日：2011-12-20

    申请号：US12956500

    申请日：2010-11-30

    申请人： Edwin Clark ,  Tallessyn Grenfell-Lee ,  Karen Lu ,  Lynn Hartmann ,  Jeffrey L. Brown ,  Robert C. Bast, Jr. ,  Gordon B. Mills

    发明人： Edwin Clark ,  Tallessyn Grenfell-Lee ,  Karen Lu ,  Lynn Hartmann ,  Jeffrey L. Brown ,  Robert C. Bast, Jr. ,  Gordon B. Mills

    IPC分类号： C12Q1/68 ,  G01N33/53

    CPC分类号： G01N33/6893 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57496 ,  G01N2500/00 ,  G01N2800/52

    摘要： The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.

    摘要翻译： 本发明涉及可用于确定肿瘤是否对治疗剂敏感或抗性的标志物的鉴定。 本发明还涉及治疗靶标的鉴定。 本发明特征在于许多“灵敏度标记物”。这些标记物在大多数或所有细胞系中表达，对于用药剂治疗敏感并且在细胞中不表达（或以相当低的水平表达） 耐药性。 本发明还具有许多“抗性标记”。这些标记物在大多数或所有细胞系中表达，其对于用药剂治疗有抗性并且在细胞中不表达（或以相当低的水平表达） 对该药物的治疗敏感。 本发明还具有可以预测可能响应或不响应于药剂的患者的标记物组。

    NOVEL COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF HUMAN CANCERS
    6.
    发明申请
    NOVEL COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF HUMAN CANCERS 审中-公开
    人类癌症鉴定，评估，预防和治疗的新组合物和方法

    公开(公告)号：US20120141604A1

    公开(公告)日：2012-06-07

    申请号：US13289230

    申请日：2011-11-04

    申请人： Edwin Clark ,  Tallessyn Grenfell-Lee ,  Karen Lu ,  Lynn Hartmann ,  Jeffrey L. Brown ,  Robert C. Bast, JR. ,  Gordon B. Mills

    发明人： Edwin Clark ,  Tallessyn Grenfell-Lee ,  Karen Lu ,  Lynn Hartmann ,  Jeffrey L. Brown ,  Robert C. Bast, JR. ,  Gordon B. Mills

    IPC分类号： C40B30/04 ,  A61K33/24 ,  A61P35/00 ,  A61K31/337

    CPC分类号： G01N33/6893 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57496 ,  G01N2500/00 ,  G01N2800/52

    摘要： The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.

    摘要翻译： 本发明涉及可用于确定肿瘤是否对治疗剂敏感或抗性的标志物的鉴定。 本发明还涉及治疗靶标的鉴定。 本发明特征在于许多“灵敏度标记物”。这些标记物在大多数或所有细胞系中表达，对于用药物治疗敏感并且在细胞中未表达（或以相当低的水平表达） 耐药性。 本发明还具有许多“抗性标记”。这些标记物在大多数或所有细胞系中表达，其对于用药剂治疗有抗性并且在细胞中不表达（或以相当低的水平表达） 对该药物的治疗敏感。 本发明还具有可以预测可能响应或不响应于药剂的患者的标记物组。